{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:12:45Z","timestamp":1767906765771,"version":"3.49.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Portuguese IBD Study Group"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Serum dipeptidyl peptidase 4 (DPP-4) has drawn particular interest as a biomarker in inflammatory bowel disease (IBD), as this protease inactivates several peptides that participate in the inflammatory cascade.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Two prospectively recruited cohorts consisting of 195 patients (101 had Crohn\u2019s disease [CD] and 94 had ulcerative colitis [UC]) were evaluated using clinical indexes and followed up to assess for treatment escalation. Sixty-eight patients underwent endoscopic evaluation at baseline. In the second cohort of 46 biologically treated patients, treatment response was assessed. Serum DPP-4, C-reactive protein (CRP), and fecal calprotectin levels were quantified at baseline and during follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Median DPP-4 levels were significantly lower in active IBD patients when compared with remitters (CD: 1043 [831\u20131412] vs 1589 [1255\u20131956] ng\/mL; P &amp;lt; 0.001; UC: 1317 [1058\u20131718] vs 1798 [1329\u20132305] ng\/mL; P = 0.001) and healthy controls (2175 [1875\u20133371] ng\/mL). In fact, DPP-4 was able to distinguish clinical and endoscopic activity from remission, with areas under the curve (AUC) of 0.81\/0.93 (CD) and 0.71\/0.79 (UC), along with the need for treatment escalation, with comparable AUCs of 0.79 (CD) and 0.77 (UC). Furthermore, DPP-4 levels were higher in responders to treatment and more pronounced among UC (1467 [1301\u20131641] vs 1211 [1011\u20131448] ng\/mL; P &amp;lt; 0.001) than CD patients (1385 [1185\u20131592] vs 1134 [975\u20131469] ng\/mL; P = 0.015).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results suggest that serum DPP-4 can be used as a noninvasive biomarker of IBD activity and biological treatment response and a predictor of treatment escalation, particularly when combined with other biomarkers.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izz319","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T12:48:05Z","timestamp":1578487685000},"page":"1707-1719","source":"Crossref","is-referenced-by-count":23,"title":["Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"26","author":[{"given":"Pedro","family":"Pinto-Lopes","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Centro Hospitalar S\u00e3o Jo\u00e3o, Porto, Portugal"},{"name":"Department of Internal Medicine, Centro Hospitalar T\u00e2mega e Sousa \u2013 Hospital Padre Am\u00e9rico, Penafiel, Portugal"},{"name":"Unit of Pharmacology and Therapeutics, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal"}]},{"given":"Joana","family":"Afonso","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology and Therapeutics, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal"},{"name":"MedInUP, Centre for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal"}]},{"given":"Rui","family":"Pinto-Lopes","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Mid Essex Hospital Services NHS Trust, Broomfield, Essex, United Kingdom"}]},{"given":"C\u00e1tia","family":"Rocha","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology and Therapeutics, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal"},{"name":"Instituto de Sa\u00fade Ambiental, Faculty of Medicine, University of Lisbon, Lisbon, Portugal"}]},{"given":"Paula","family":"Lago","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Centro Hospitalar do Porto, Porto, Portugal"}]},{"given":"Raquel","family":"Gonc\u0327alves","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital de Braga, Braga, Portugal"}]},{"given":"Helena","family":"Tavares De Sousa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Centro Hospitalar e Universit\u00e1rio do Algarve \u2013 Portim\u00e3o Unit, Portim\u00e3o, Portugal"},{"name":"Department of Medicine and Medical Biosciences, University of Algarve, Faro, Portugal"}]},{"given":"Guilherme","family":"Macedo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Centro Hospitalar S\u00e3o Jo\u00e3o, Porto, Portugal"}]},{"given":"Cl\u00e1udia","family":"Camila Dias","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal"},{"name":"CINTESIS \u2013 Centre for Health Technology and Services Research, Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology and Therapeutics, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal"},{"name":"Department of Gastroenterology, Faculty of Medicine, Centro Hospitalar S\u00e3o Jo\u00e3o, Porto, Portugal"}]}],"member":"286","published-online":{"date-parts":[[2020,1,8]]},"reference":[{"key":"2020102313005254000_CIT0001","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1146\/annurev-immunol-030409-101225","article-title":"Inflammatory bowel disease","volume":"28","author":"Kaser","year":"2010","journal-title":"Annu Rev Immunol."},{"key":"2020102313005254000_CIT0002","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/mi.2013.73","article-title":"New targets for mucosal healing and therapy in inflammatory bowel diseases","volume":"7","author":"Neurath","year":"2014","journal-title":"Mucosal Immunol."},{"key":"2020102313005254000_CIT0003","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1053\/j.gastro.2015.01.026","article-title":"Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn\u2019s disease after surgery","volume":"148","author":"Wright","year":"2015","journal-title":"Gastroenterology."},{"key":"2020102313005254000_CIT0004","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/gut.2004.043406","article-title":"Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn\u2019s disease","volume":"54","author":"Costa","year":"2005","journal-title":"Gut."},{"key":"2020102313005254000_CIT0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2036.16.s4.18.x","article-title":"Review article: monitoring the activity of Crohn\u2019s disease","volume":"16","author":"Biancone","year":"2002","journal-title":"Aliment Pharmacol Ther."},{"key":"2020102313005254000_CIT0006","doi-asserted-by":"crossref","first-page":"e678","DOI":"10.1016\/j.crohns.2013.06.008","article-title":"Serum calprotectin as a biomarker for Crohn\u2019s disease","volume":"7","author":"Meuwis","year":"2013","journal-title":"J Crohns Colitis."},{"key":"2020102313005254000_CIT0007","doi-asserted-by":"crossref","first-page":"R1057","DOI":"10.1152\/ajpregu.2000.278.4.R1057","article-title":"Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease","volume":"278","author":"Xiao","year":"2000","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"2020102313005254000_CIT0008","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/003655201750422675","article-title":"Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease","volume":"36","author":"Hildebrandt","year":"2001","journal-title":"Scand J Gastroenterol."},{"key":"2020102313005254000_CIT0009","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.regpep.2012.04.006","article-title":"Dipeptidyl peptidase-4 expression is reduced in Crohn\u2019s disease","volume":"177","author":"Moran","year":"2012","journal-title":"Regul Pept."},{"key":"2020102313005254000_CIT0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1042\/CS20040302","article-title":"Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders","volume":"108","author":"Gorrell","year":"2005","journal-title":"Clin Sci (Lond)."},{"key":"2020102313005254000_CIT0011","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut."},{"key":"2020102313005254000_CIT0012","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet."},{"key":"2020102313005254000_CIT0013","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med."},{"key":"2020102313005254000_CIT0014","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1172\/JCI59255","article-title":"Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis","volume":"121","author":"Lee","year":"2011","journal-title":"J Clin Invest."},{"key":"2020102313005254000_CIT0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.crohns.2011.07.011","article-title":"Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn\u2019s disease: a large single centre experience","volume":"6","author":"Sprakes","year":"2012","journal-title":"J Crohns Colitis."},{"key":"2020102313005254000_CIT0016","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med."},{"key":"2020102313005254000_CIT0017","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/MIB.0000000000000273","article-title":"Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn\u2019s disease","volume":"21","author":"Boschetti","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"2020102313005254000_CIT0018","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/ajg.2016.342","article-title":"Serum calprotectin: a novel diagnostic and prognostic marker in inflammatory bowel diseases","volume":"111","author":"Kalla","year":"2016","journal-title":"Am J Gastroenterol."},{"key":"2020102313005254000_CIT0019","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol."},{"key":"2020102313005254000_CIT0020","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0016-5085(90)90613-6","article-title":"Predictability of the postoperative course of Crohn\u2019s disease","volume":"99","author":"Rutgeerts","year":"1990","journal-title":"Gastroenterology."},{"key":"2020102313005254000_CIT0021","doi-asserted-by":"crossref","first-page":"k872","DOI":"10.1136\/bmj.k872","article-title":"Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study","volume":"360","author":"Abrahami","year":"2018","journal-title":"BMJ."},{"key":"2020102313005254000_CIT0022","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1136\/annrheumdis-2014-205216","article-title":"Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study","volume":"74","author":"Kim","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"2020102313005254000_CIT0023","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/1060028019827852","article-title":"Dipeptidyl peptidase-4 inhibitors and inflammatory bowel disease risk: a meta-analysis","volume":"53","author":"Radel","year":"2019","journal-title":"Ann Pharmacother."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/26\/11\/1707\/33999679\/izz319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/26\/11\/1707\/33999679\/izz319.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T17:02:43Z","timestamp":1603472563000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/26\/11\/1707\/5698249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,1,8]]},"published-print":{"date-parts":[[2020,10,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izz319","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,1,8]]}}}